Company Profile

ReGenX Biosciences LLC
Profile last edited on: 4/4/18      CAGE: 5C3S3      UEI:

Business Identifier: Therapeutics and research tools based on adeno-associated viral (AAV) vectors
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9600 Blackwell Road Suite 210
Rockville, MD 20850
   (240) 552-8181
Location: Single
Congr. District: 08
County: Montgomery

Public Profile

Previously doing business as as REGENX Biosciences, LLC, the name of the firm was changed REGENXBIO Inc. in September 2014. REGENXBIO Inc., a clinical-stage biotechnology company providing gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The firm's gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. In 2013 ReGenX, along with Fidelity Biosciences, spun off Dimension Therapeutics to develop and commercialize products based off of technology developed by ReGenX. In August 217, REGENXBIO agreed to acquire rare metabolic disease-focused Dimension Therapeutics but in October 2107 was outbid by Ultragenyx Pharmaceutical Inc.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Kenneth T Mills -- Founder, President and CEO

  Sara Garon Berl -- Vice President, Legal Affairs

  James W Brown -- Chief Operating Officer

  Karen Kozarsky -- Former Vice President Research and Development

  Katherine Maynard -- Vice President, Public Affairs and Alliance Development

  Maritza Mcintyre -- Vice President Regulatory Affairs

  Vit Vasista -- Chief Financial Officer